Drug	Availability	Dose	Frequency	Cost per month (generic)*	Uroselective?	Route of elimination	Comments
Darifenacin (Enablex)	ER tablet: 7.5, 15 mg	7.5 to 15 mg	Once daily without regard for meals	$96	Yes	Hepatic (CYP 3A4)	Dose should be decreased in patients with moderate hepatic impairment; not recommended for use in patients with severe hepatic impairment.
Oxybutynin (Ditropan; Ditropan XL)	IR tablet: 5 mg	2.5 to 5 mg	Two to four times daily	(13 to 30)	No	Hepatic (CYP 3A4)	No formal recommendations exist for dosing in patients with hepatic impairment, but extensive hepatic elimination warrants caution in this setting .
	IR syrup: 5 mg per 5 mL	2.5 to 5 mg	Two to four times daily	75 to 113 (24 to 36)
	ER tablet: 5, 10, 15 mg	5 to 30 mg	Once daily	100 to 112
Oxybutynin patch (Oxytrol)	Transdermal patch: 36 mg	1 patch	Every three to four days	93
Solifenacin (Vesicare)	Tablet: 5, 10 mg	5 to 10 mg	Once daily	101	Yes	Hepatic (CYP 3A4)/Renal	Dose should be decreased in patients with moderate hepatic or severe renal impairment; not recommended for use in patients with severe hepatic impairment. Approximately 15 percent is eliminated unchanged in the urine.
Tolterodine (Detrol; Detrol LA)	IR tablet: 1, 2 mg	1 to 2 mg	Twice daily	112 to 115	No	Hepatic (CYP 2D6/3A4)	Lowest dose should be used in patients with severe hepatic or renal impairment who are taking CYP 3A4 inhibitors. Tolterodine has a lesser effect at the salivary gland than oxybutynin.
Tolterodine (Detrol; Detrol LA)	ER capsule: 2, 4 mg	2 to 4 mg	Once daily	97 to 100	No	Hepatic (CYP 2D6/3A4)
Trospium (Sanctura)	Tablet: 20 mg	20 mg	Twice daily at least one hour before meals or on an empty stomach	89	No	Renal	May have functional selectivity Administer once daily in patients with severe renal impairment.